Azitra Inc (AZTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Azitra Inc (AZTR) has a cash flow conversion efficiency ratio of -0.761x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($3.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Azitra Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Azitra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Azitra Inc for a breakdown of total debt and financial obligations.
Azitra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Azitra Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STS Global Income & Growth Trust PLC
LSE:STS
|
0.011x |
|
Raja Ferry Port Public Company Limited
BK:RP
|
0.059x |
|
EQTEC plc
LSE:EQT
|
-0.273x |
|
Li Bang International Corporation Inc. Ordinary Shares
NASDAQ:LBGJ
|
0.033x |
|
De La Rue PLC
LSE:DLAR
|
2.021x |
|
The Biotech Growth Trust PLC
LSE:BIOG
|
-0.010x |
|
Harfang Exploration Inc
V:HAR
|
-0.050x |
|
Tree House Education & Accessories Limited
NSE:TREEHOUSE
|
0.000x |
Annual Cash Flow Conversion Efficiency for Azitra Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Azitra Inc from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Azitra Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.80 Billion | $-11.22 Million | -0.003x | +99.83% |
| 2024-12-31 | $5.70 Million | $-10.18 Million | -1.787x | +29.29% |
| 2023-12-31 | $2.91 Million | $-7.36 Million | -2.527x | -1197.56% |
| 2022-12-31 | $-36.26 Million | $-8.35 Million | 0.230x | -26.46% |
| 2021-12-31 | $-25.77 Million | $-8.07 Million | 0.313x | -- |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more